Ohmium International Appoints Veteran Energy Sector Leader as New CEO to Accelerate Global Growth and Scale
18.6.2025 10:59:00 EEST | Business Wire | Press release
Ohmium International, a leading manufacturer of advanced PEM hydrogen electrolyzers, announced the appointment of Dr. Markus Tacke as its new CEO, effective July 1, 2025. With over 22 years of experience at Siemens and a proven track record in the renewable energy sector, Dr. Tacke will drive Ohmium's global expansion and commercialization of its next-generation green hydrogen solutions.
Dr. Tacke has a history of growing companies in energy, infrastructure, manufacturing, and technology. His focus on customer centricity, operational efficiency, and strategic acquisitions has consistently driven growth and value. As CEO of Oerlikon Surface Solutions AG, he achieved 8% annual growth and turned the company from break-even to 9% profitability through regional integration and new business exploration. At Siemens Gamesa Renewable Energy, he streamlined product lines, launched advanced platforms, and initiated a €2.5 billion cost savings program, stabilizing the wind business and launching a high-impact growth strategy.
“Dr. Markus Tacke possesses a rare blend of operational excellence and technical expertise, along with a strong history of scaling businesses,” said Ahmad Chatila, Board Chairman of Ohmium. “His unique combination of skills will be pivotal as we expand globally and deepen our commercial partnerships. We are confident he will help us meet and exceed our ambitious goals.”
Arne Ballantine, the former CEO and co-founder of Ohmium International, has steered the company through its formative years. Under his leadership, Ohmium developed a robust internal PEM supply chain capable of scaling to meet gigawatt-level demand and successfully deployed its products globally across multiple sites.
Ballantine expressed deep enthusiasm and excitement for the company’s future, stating, “Leading Ohmium through its early stages has been an incredible privilege. I am immensely proud of our team and their achievements, including securing numerous patents and gaining industry recognition for our high efficiency, rapidly scalable, and bankable PEM electrolyzer. I have full confidence that Dr. Tacke is the right leader to guide us into the future. I look forward to supporting the transition and seeing the company continue to grow.”
The company is focused on further commercial deployments, manufacturing scale-up, and international market expansion. With the rising global demand for clean, reliable, and affordable energy, Ohmium is well-positioned to assist in the decarbonization of hard-to-abate sectors worldwide.
“I am honored to join Ohmium International at such an exciting inflection point,” said Dr. Tacke. “Ohmium’s technology, team, and culture are extraordinary. I look forward to working alongside our employees, clients, investors, and partners to accelerate the transition to a greener future on a global scale.”
Dr. Tacke earned a Mechanical Engineering degree and a PhD from the Technical University of Darmstadt, Germany, and a Master’s degree in Engineering from Cornell University in New York, USA.
ABOUT OHMIUM
Ohmium designs, manufactures, and deploys modular, scalable Proton Exchange Membrane (PEM) electrolyzers that enable cost-competitive green hydrogen production. The company’s suite of electrochemical products helps customers achieve their sustainable energy goals across various industrial, transportation, and energy projects. Headquartered in the United States with manufacturing facilities in India and operations worldwide, Ohmium has a global green hydrogen project pipeline exceeding 2 GW across three continents. In 2023, Ohmium raised $250 Million in Series C financing, led by TPG Rise Climate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618955897/en/
Contacts
Maria Quan
Ohmium International
VP, Marketing
maria.quan@ohmium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom